CAMP4 THERAPEUTICS CORPORATION
Ownership
Ownership Structure
Who owns CAMP4 THERAPEUTICS CORPORATION (CAMP)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 69.1% of the shares are freely tradable; institutional investors hold 86.6%.
Largest Shareholders
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Fidelity Select Biotechnology | 4.07 | 2,552,814 | +92.5 | 08/31/2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 2.54 | 1,594,579 | +28.8 | 09/30/2026 |
| Fidelity Growth Company Fund | 1.31 | 821,773 | +105.7 | 08/31/2026 |
| iShares Russell 2000 ETF | 1.14 | 717,977 | -1.1 | 09/30/2026 |
| Fidelity Small Cap Index | 0.54 | 341,836 | -0.1 | 07/31/2026 |
| iShares Russell 2000 Growth ETF | 0.48 | 299,757 | -0.1 | 09/30/2026 |
| Fidelity Growth Company K6 | 0.37 | 235,164 | +113.8 | 08/31/2026 |
| Victory Science & Technology | 0.36 | 226,602 | +0.0 | 09/30/2026 |
| Vanguard Russell 2000 ETF | 0.29 | 183,101 | +1.3 | 09/30/2026 |
| Fidelity Series Growth Company | 0.26 | 166,138 | +175.9 | 08/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Schwab Andrew J. | Director | 2,033,270 | 7,726,426 $ | Aug 27, 2026 | indirect |
| Mandel-Brehm Josh | Chief Executive Officer | 284,968 | 1,082,878 $ | Aug 3, 2026 | direct |
| Young Richard A | Director | 186,388 | 708,274 $ | Aug 3, 2026 | direct |
| Gold Kelly | Chief Financial Officer | 84,428 | 320,826 $ | Aug 3, 2026 | both |
| Maricich Yuri | Chief Medical Officer | 12,611 | 47,922 $ | Aug 3, 2026 | direct |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 31, 2026 | Gold Kelly | Chief Financial Officer | Buy | 10,000 | 3.96 | 39,600 |
| Aug 27, 2026 | Schwab Andrew J. | Director | Sell | 400,000 | 4.04 | 1,616,000 |
| Aug 24, 2026 | Schwab Andrew J. | Director | Sell | 10 | 4.50 | 45 |
| Aug 21, 2026 | Schwab Andrew J. | Director | Sell | 32,018 | 4.50 | 144,081 |
| Aug 20, 2026 | Schwab Andrew J. | Director | Sell | 114,700 | 4.54 | 520,738 |
| Aug 19, 2026 | Schwab Andrew J. | Director | Sell | 45,147 | 4.76 | 214,900 |
| Aug 19, 2026 | Tardiff Daniel | Chief Scientific Officer | Sell | 1,738 | 4.76 | 8,273 |
| Aug 3, 2026 | Young Richard A | Director | Buy | 16,378 | 1.65 | 27,024 |
| Aug 3, 2026 | Maricich Yuri | Chief Medical Officer | Buy | 6,551 | 1.65 | 10,809 |
| Aug 3, 2026 | Gold Kelly | Chief Financial Officer | Buy | 6,551 | 1.65 | 10,809 |
| Aug 3, 2026 | Mandel-Brehm Josh | Chief Executive Officer | Buy | 6,551 | 1.65 | 10,809 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: November 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.